Recent Updates — ASPI

Tetra4 Proprietary Limited, a subsidiary of Renergen Limited and an affiliate of ASP Isotopes Inc., has completed commissioning and achieved stable production of liquid helium at its Virginia Gas Project in South Africa. Liquid helium is now accumulating in cryogenic storage ahead of initial deliveries under existing offtake agreements. Phase 1 is expected to produce approximately 2,500 GJ/day of liquefied natural gas (LNG) and 70 Mcf/day of liquid helium, with nameplate capacity expected during the fourth quarter of 2026. ASP Isotopes Inc. is an advanced materials company focused on developing technologies for the production of critical isotopes used in nuclear medicine, electronics, and nuclear energy.

Quantum Leap Energy, a wholly-owned subsidiary of ASP Isotopes Inc., signed a binding Heads of Agreement with the Nuclear Energy Corporation of South Africa (Necsa) to establish a joint venture. The partnership will develop, finance, and operate a test bench and commercial-scale facility for producing High-Assay Low-Enriched Uranium (HALEU) at Necsa's Pelindaba site in South Africa. Quantum Leap Energy will hold approximately 80% ownership and lead operations, while Necsa contributes site access, regulatory support, and infrastructure. The project already has secured offtake agreements with TerraPower for the produced HALEU. ASP Isotopes Inc. is an advanced materials company focused on developing technologies and processes for the production of critical isotopes used in nuclear medicine, electronics, and nuclear energy.

ASP Isotopes Inc. filed a Form 8-K to disclose that ENDRA Life Sciences Inc. submitted a Registration Statement on Form S-4 with the SEC regarding their proposed merger transaction. The Merger Agreement, originally signed on June 25, 2026, involves ASP Isotopes' subsidiary Noble Africa merging into Merger Sub, a subsidiary of ENDRA, resulting in Noble Africa surviving as a wholly-owned subsidiary of ENDRA. This filing incorporates by reference information from the Form S-4, which includes details about Renergen Limited, another ASP Isotopes subsidiary involved in the strategic combination. The transaction is subject to customary closing conditions and regulatory approvals. ASP Isotopes Inc. operates in the nuclear medicine and isotopes industry.

ASP Isotopes Inc.'s subsidiary, Renergen Limited, entered into a Second Amendment and Restatement Agreement with The Standard Bank of South Africa Limited on August 14, 2026. This agreement replaced the prior term loan facility, increasing the aggregate principal amount to ZAR 230,532,658.90 (approximately USD 14,212,864). The new secured loan matures on August 14, 2027, with interest accruing at a compounded reference rate plus 1.46%, resulting in an effective annual rate of 8.31%. Security includes a collateral account controlled by the lender and a pledge of 1,546,268 shares of ASP Isotopes common stock held by NTIGT Investments. A Put Option Agreement grants the lender the right to require the purchase of these pledged shares upon default. The company operates in the nuclear energy sector, focusing on isotope production.

ASP Isotopes Inc. announced on August 20, 2026, that Tetra4 Proprietary Limited has entered the commissioning phase of its Phase 1 liquid helium plant in South Africa. Commercial production is expected to commence in September 2026, with ramp-up to nameplate capacity targeted for the second half of 2026. Phase 1 is projected to produce approximately 70 Mcf/day of liquid helium and 2,500 GJ/day of LNG, potentially generating over $27 million in annualized revenues based on assumed pricing. The company has secured take-or-pay contracts for roughly 75% of Phase 1 LNG and 15% of its helium output. Construction of the significantly larger Phase 2 is planned to begin in late 2026, with up to $750 million in senior debt funding sought from the U.S. International Development Finance Corporation and Standard Bank of South Africa. ASP Isotopes operates an advanced materials company focused on developing technologies for the production of critical isotopes used in nuclear medicine, semiconductors, and energy.